GSK (GSK) Jefferies Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference 2026 summary
3 Jun, 2026Strategic portfolio decisions
Shifted focus from broad checkpoint inhibitor exploration to precision oncology and validated platforms, optimizing risk and success probability.
Continued development of Blenrep despite early mixed results, leading to positive outcomes in DREAMM-7 and DREAMM-8 studies.
Prioritized dostarlimab in competitive PD-1/PD-L1 space, targeting under-served indications like first-line endometrial and dMMR MSI-High cancers.
Leveraged business development, acquiring assets like Sierra Oncology (momelotinib) and IDRx (velzatinib) to complement the pipeline.
Internal vs. external innovation and technology integration
Emphasizes a balanced approach to sourcing innovation, combining internal strengths with external opportunities globally.
Strategic focus on prioritized disease areas and technologies, benchmarking internal and external assets for best-in-class potential.
AI and machine learning are embedded across discovery and translational research, supporting antigen discovery, medicinal chemistry, and disease modeling.
Acquired CELLphenomics to advance organoid-based in vitro models, enhancing translational insights and predictive capabilities.
Computational pathology and digital biomarker assessment are being evaluated to improve diagnostics and patient stratification.
Antibody-drug conjugates (ADCs) and biomarker strategy
ADCs are evaluated by antigen selectivity, linker stability, and payload potency, with a focus on optimizing dosing and multivariate biomarkers.
B7-H4 ADC shows strong efficacy in gynecological cancers, with 62% response in platinum-resistant ovarian and 67% in second-line endometrial cancer.
B7-H3 ADC targets a broad range of tumors, with upcoming phase III studies and new data expected in the next 6–12 months.
Combination strategies with checkpoint inhibitors like dostarlimab are pursued where clinically and commercially justified.
Latest events from GSK
- GBP 1.9bn savings and 22 Phase III starts fuel a >GBP 40bn 2031 sales ambition.GSK
J.P. Morgan UK Leaders Conference - Four- and six-month HIV regimens, pipeline launches and oncology aim to sustain growth through expiries.GSK
Jefferies Global Healthcare Conference - Biomarker-led R&D advances long-acting airway therapies and novel liver programs.GSK
3rd Annual Guggenheim Healthcare Innovation Conference - Specialty-led growth and pipeline investment support reaffirmed FY26 guidance.GSK
Q3 2026 - Oncology data highlighted gains across ADCs, immunotherapy and targeted therapies.GSK
ESMO 2026 Investor Briefing - 14% CER sales growth and upgraded outlooks to >£38bn sales by 2031.GSK
Q4 2023 - Ultra-long-acting biologics, AI-driven R&D, and global partnerships are shaping future growth.GSK
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - GBP 1.9bn in savings will fund pipeline growth, with oncology and specialty assets prioritized.GSK
Bank of America Global Healthcare Conference - Rapid portfolio growth and robust clinical data position oncology for major advances by 2031.GSK
Morgan Stanley 24th Annual Global Healthcare Conference - Accelerated R&D, pipeline reinvestment, and specialty focus drive growth and margin stability.GSK
Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference